Best medication for Overactive bladder, honestly
Overactive bladder means urgency — a sudden need to go that is hard to defer — usually with frequency, often with nighttime trips, sometimes with leaking. Seven oral drugs are covered here, in eight formulations, and they split into two groups that behave very differently: the older anticholinergics (antimuscarinics) and the newer beta-3 agonists. These are the common scenarios, not a complete rulebook, and not the full US list — fesoterodine (Toviaz) is a further antimuscarinic, and oxybutynin also comes as a skin patch and a topical gel, which cause less dry mouth by bypassing first-pass metabolism. The choice between the two groups is not mainly about which works better on average — head-to-head, the effect sizes are broadly similar and modest. It is about which side-effect profile you can live with, what else you take, and how old you are. The order on this page reflects the label facts that decide fit — anticholinergic burden, blood-pressure effects, and dosing constraints — not a claim that the top entry works best; our FDA recall-safety score is shown on each drug page. This is not medical advice; the prescribing decision is your clinician's.
The first-line treatment for overactive bladder is not a drug
Behavioral therapy comes first in urology guidelines: timed voiding and bladder training to stretch the interval between trips, pelvic floor muscle exercises, urge-suppression technique, and cutting back on the specific fluids that provoke you — caffeine, alcohol, and, for some people, carbonation and artificial sweeteners. This is not a filler recommendation before the real treatment. It works, it stacks with medication, and it has no side effects. Drugs are added when behavioral therapy alone is not enough. Among the drugs, here is the distinction competitor listicles bury. The older anticholinergics — oxybutynin, tolterodine, solifenacin, darifenacin, trospium — block muscarinic receptors everywhere, not just in the bladder. Dry mouth and constipation are the class complaints and the usual reason people quit, and in older adults these drugs add to total anticholinergic burden, which is associated with confusion, sedation, and falls. Oxybutynin, the cheapest and most-prescribed of them, is also the one with the most central nervous system penetration. The American Geriatrics Society Beers Criteria flags oral antimuscarinics for overactive bladder as potentially inappropriate in older adults, particularly those with dementia or cognitive impairment — and older adults are exactly who gets prescribed them most. The beta-3 agonists, mirabegron and vibegron, relax the bladder by a different mechanism and add no anticholinergic burden, which is the specific geriatric risk. That is not the same as zero CNS risk: mirabegron's label lists postmarketing reports of confusion, hallucinations, insomnia and anxiety, mostly in people who had other causes present, with no causal relationship established. The other trade-offs are real too: mirabegron can raise blood pressure, and both are newer and usually more expensive. And both classes carry a labeled warning for angioedema — airway swelling that can appear after the very first dose.
Behavioral therapy (bladder training, pelvic floor exercises, fluid triggers)
Non-drug — first-line
Not a medication — the first tier in urology guidelines, before any prescription. Timed voiding and bladder training to lengthen the interval between trips, pelvic floor muscle training (ask for pelvic floor physical therapy if self-directed exercises are not landing), urge-suppression technique, and cutting the fluids that provoke you — caffeine and alcohol first. No side effects, no interactions, and it keeps working alongside whatever drug is added later.
Trospium chloride
Anticholinergic (antimuscarinic)
20 mg twice daily, taken on an empty stomach at least one hour before meals — food substantially reduces absorption, so timing is not optional. Chemically a quaternary ammonium compound, which crosses the blood-brain barrier poorly; that is why it is often the antimuscarinic chosen when cognitive side effects are the concern. It still causes dry mouth and constipation, and it still adds to total anticholinergic burden. Renal dosing: with creatinine clearance under 30 mL/min, 20 mg once daily at bedtime; at age 75 and older the dose may be titrated down to 20 mg once daily on tolerability. Labeled caution in ulcerative colitis, intestinal atony and myasthenia gravis, because it slows the gut and blocks the same receptors. Contraindicated in urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, or being at risk for those, and in known hypersensitivity to trospium. Labeled warning: angioedema and anaphylactic reactions — swelling of the face, lips, tongue or larynx, reported after the first dose. Upper-airway swelling can be life-threatening; stop the drug and get emergency care. No FDA boxed warning. Labeled caution in moderate and severe hepatic impairment (no dose cap specified).
Solifenacin (Vesicare)
Anticholinergic (antimuscarinic)
5 mg once daily, increased to 10 mg if tolerated. Available generically. Do not exceed 5 mg with a strong CYP3A4 inhibitor (for example ketoconazole), with creatinine clearance under 30 mL/min (the label writes this as mL/min/1.73m²), or with moderate hepatic impairment (Child-Pugh B); not recommended in severe hepatic impairment (Child-Pugh C). QT, stated as the label states it: the thorough QT study raised the Fridericia-corrected QT interval by about 8 msec at 30 mg — three times the maximum recommended dose — and by about 2 msec at 10 mg. The label's restriction is about the person, not the dose: solifenacin is not recommended at any dose in people at high risk of QT prolongation, including a known history of QT prolongation or any concurrent QT-prolonging drug. Contraindicated in urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and known hypersensitivity to solifenacin; not recommended when gastrointestinal motility is already decreased. Labeled warning: angioedema and anaphylactic reactions — swelling of the face, lips, tongue or larynx, sometimes after the very first dose and sometimes after later doses. Upper-airway swelling can be life-threatening; stop the drug and get emergency care. Anticholinergic burden applies. No FDA boxed warning.
Darifenacin (Enablex)
Anticholinergic (antimuscarinic)
7.5 mg once daily, may be increased to 15 mg as early as two weeks in; extended-release tablet, swallow whole, do not chew or crush. Relatively M3-selective, which is the theoretical argument for it; in practice dry mouth and constipation are still the dominant complaints, and constipation is prominent with this one. Daily dose capped at 7.5 mg with a potent CYP3A4 inhibitor (ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, nefazodone) or in moderate hepatic impairment (Child-Pugh B); not recommended in severe hepatic impairment (Child-Pugh C). Labeled caution in severe constipation, ulcerative colitis and myasthenia gravis. Contraindicated in — or at risk for — urinary retention, gastric retention, and uncontrolled narrow-angle glaucoma. Labeled warning: angioedema — swelling of the face, lips, tongue or larynx, reported after the first dose. Upper-airway swelling can be life-threatening; stop the drug and get emergency care. Anticholinergic burden applies. No FDA boxed warning.
Oxybutynin ER (Ditropan XL)
Anticholinergic (antimuscarinic)
5 to 30 mg once daily, swallowed whole and never crushed or chewed; the empty tablet shell can appear in stool, which is expected. Cheap and widely generic. Oxybutynin has the most central nervous system penetration of this group and is the antimuscarinic most consistently singled out in geriatric prescribing guidance — the Beers Criteria advise against oral antimuscarinics for overactive bladder in older adults with dementia or cognitive impairment. The ER form is easier to tolerate than immediate-release, but the cognitive concern does not disappear with the formulation. Labeled caution where symptoms can be aggravated: pre-existing dementia treated with a cholinesterase inhibitor, Parkinson's disease, myasthenia gravis, and decreased gastrointestinal motility in autonomic neuropathy. Contraindicated in urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma, and known hypersensitivity to oxybutynin. Labeled warning: angioedema and anaphylactic reactions — swelling of the face, lips, tongue or larynx, reported after the first dose. Upper-airway swelling can be life-threatening; stop the drug and get emergency care. No FDA boxed warning. No numeric renal or hepatic adjustment exists — oxybutynin was not studied in either, and the label advises caution in both.
Vibegron (Gemtesa)
Beta-3 agonist
75 mg once daily, with or without food; the tablet may be crushed and mixed with applesauce, which matters for people who struggle with pills. Non-anticholinergic mechanism, so no dry-mouth/constipation burden and nothing added to anticholinergic load — the reason beta-3 agonists are preferred over the antimuscarinics in adults 65 and older. Unlike mirabegron, its labeling carries no blood-pressure restriction. No dose adjustment is needed for mild-to-severe renal impairment or Child-Pugh A or B, but it is not recommended below an eGFR of 15 mL/min/1.73m², on dialysis, or in severe hepatic impairment (Child-Pugh C). It is also the only drug on this page with a separate FDA indication for overactive bladder in adult men already on drug therapy for benign prostatic hyperplasia. It raises digoxin levels — digoxin should be monitored. Labeled warning: urinary retention, especially with bladder outlet obstruction or a concurrent antimuscarinic; discontinue if retention develops. Labeled warning: angioedema — swelling of the face, lips, tongue or larynx, reported hours after the first dose or after multiple doses. Upper-airway swelling can be life-threatening; stop the drug and get emergency care. Contraindicated after any prior hypersensitivity reaction to vibegron. No FDA boxed warning. Usually brand-priced.
Mirabegron (Myrbetriq)
Beta-3 agonist
25 mg once daily to start, raised to 50 mg after 4 to 8 weeks if needed; swallowed whole, not chewed or crushed. No anticholinergic burden — the reason beta-3 agonists are preferred over the antimuscarinics in adults 65 and older. The honest caveat is blood pressure: mirabegron raises it, and the label says it is not recommended in severe uncontrolled hypertension (systolic 180 mmHg or higher and/or diastolic 110 mmHg or higher). Check BP before starting and periodically after. The dose caps a listicle will not tell you: maximum 25 mg once daily with an eGFR of 15 to 29 mL/min/1.73m² or moderate hepatic impairment (Child-Pugh B), and not recommended at all with an eGFR under 15, on dialysis, or in severe hepatic impairment (Child-Pugh C). It inhibits CYP2D6, so it can raise levels of metoprolol, desipramine, flecainide and similar drugs, and it raises digoxin levels. Labeled warning: urinary retention, higher risk with bladder outlet obstruction or a concurrent antimuscarinic. Labeled warning: angioedema — swelling of the face, lips, tongue or larynx, reported hours after the first dose or after multiple doses. Upper-airway swelling can be life-threatening; stop the drug and get emergency care. Contraindicated after a known hypersensitivity reaction to mirabegron. No FDA boxed warning.
Tolterodine ER (Detrol LA)
Anticholinergic (antimuscarinic)
4 mg once daily as the extended-release capsule, swallowed whole; generic. Reduce to 2 mg daily with a strong CYP3A4 inhibitor, a creatinine clearance of 10-30 mL/min, or mild-to-moderate hepatic impairment (Child-Pugh A or B); it is not recommended at all below a creatinine clearance of 10 mL/min or in severe hepatic impairment (Child-Pugh C), where the answer is a different drug, not a lower dose. Generally causes less dry mouth than oxybutynin, which is its main reason for being chosen over it, but it is still an antimuscarinic and still adds to anticholinergic burden in older adults. It is not the QT-clean antimuscarinic: the label directs prescribers to weigh its thorough-QT findings — a concentration-dependent effect, larger in CYP2D6 poor metabolizers — before prescribing to anyone with known QT prolongation or taking a Class IA (quinidine, procainamide) or Class III (amiodarone, sotalol) antiarrhythmic. Labeled caution in myasthenia gravis and in gastrointestinal obstructive disorders or decreased GI motility. Contraindicated in urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in anyone with a known hypersensitivity to tolterodine or to fesoterodine (Toviaz) — both are metabolized to the same active compound. Labeled warning: angioedema and anaphylactic reactions — swelling of the face, lips, tongue or larynx, sometimes after the very first dose and sometimes after later doses. Upper-airway swelling can be life-threatening; stop the drug and get emergency care. No FDA boxed warning.
Oxybutynin IR (Ditropan)
Anticholinergic (antimuscarinic)
Immediate-release oxybutynin, typically 5 mg two or three times daily. It is the least expensive option on this page and the one most likely to be stopped: peak-and-trough dosing produces the most dry mouth, blurred vision, constipation and drowsiness of any drug here, plus the highest cognitive risk in older adults. Reasonable as a short trial or when cost genuinely governs, and some people use it situationally; it is a poor default for anyone over 65. Same labeled cautions as the ER form — pre-existing dementia on a cholinesterase inhibitor, Parkinson's disease, myasthenia gravis. Contraindicated in urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma, and known hypersensitivity to oxybutynin. Anticholinergics also reduce sweating, raising heat-stroke risk in hot weather. Labeled warning: angioedema and anaphylactic reactions — swelling of the face, lips, tongue or larynx, reported after the first dose. Upper-airway swelling can be life-threatening; stop the drug and get emergency care. No FDA boxed warning. No numeric renal or hepatic adjustment exists — oxybutynin was not studied in either, and the label advises caution in both.
How to choose
The honest way to narrow it down — matched to your situation, not a ranking. These are common scenarios, not a complete rulebook; the final choice is a prescriber’s.
- You have not yet tried bladder training, timed voiding, pelvic floor exercises, or cutting caffeine and alcohol
- Start there — it is guideline first-line, and it also makes whatever drug you add later work better. Ask for a referral to pelvic floor physical therapy if self-directed exercises are not landing.
- You are over 65, have memory concerns or dementia, or already take other anticholinergic drugs (some antihistamines, tricyclics, certain bladder and sleep medicines)
- A beta-3 agonist — vibegron or mirabegron — because neither adds anticholinergic burden, and guidelines prefer them over the antimuscarinics in this age group. Oxybutynin is the specific drug to avoid here.
- Your blood pressure is high and not controlled, your kidney or liver function is reduced, or you take a strong CYP3A4 inhibitor
- Dose limits apply and differ by drug. Mirabegron is the poor fit for uncontrolled hypertension — not recommended at 180/110 mmHg or above — and it is capped at 25 mg daily with an eGFR of 15–29 mL/min/1.73m² or Child-Pugh B, and not recommended below eGFR 15, on dialysis, or in Child-Pugh C. Vibegron carries no blood-pressure restriction, but its own label does not recommend it either below an eGFR of 15 mL/min/1.73m², on dialysis, or in Child-Pugh C. Solifenacin is capped at 5 mg, darifenacin at 7.5 mg (hepatic or CYP3A4 only — it has no renal adjustment), tolterodine ER at 2 mg, and trospium moves to 20 mg once daily at bedtime under 30 mL/min. Trospium carries a labeled caution in moderate and severe hepatic impairment with no dose cap specified, and oxybutynin has no numeric adjustment at all — it was never studied in renal or hepatic impairment and its label simply advises caution in both. Bring your full medication list to the visit.
- You have an obstructive bowel condition, severe ulcerative colitis, gastroparesis or chronic constipation, or myasthenia gravis
- The antimuscarinics are contraindicated or carry a labeled caution here — they slow the gut further and blunt the same receptors weakened in myasthenia. A beta-3 agonist avoids that mechanism entirely.
- Dry mouth or constipation from one antimuscarinic is intolerable
- Two reasonable moves: switch to a different antimuscarinic (tolterodine and trospium are often better tolerated for dry mouth than oxybutynin), or leave the class entirely for a beta-3 agonist. If you have long QT or take a QT-prolonging drug, note that both solifenacin and tolterodine carry QT language on their labels — that switch is not QT-neutral.
- Cost is the deciding factor
- The generic antimuscarinics — oxybutynin ER, tolterodine ER, solifenacin, trospium — are the cheapest route. Weigh that against age and cognitive risk before defaulting to immediate-release oxybutynin.
- You are a man with an enlarged prostate or a known bladder outlet obstruction
- Every drug here can worsen urinary retention, and the obstruction itself needs assessment first. Worth knowing for that conversation: vibegron is the only drug on this page separately FDA-approved for overactive bladder symptoms in adult men already on drug therapy for benign prostatic hyperplasia. The antimuscarinics carry the most retention risk in this group.
Overactive bladder medications at a glance
| Drug | Class | How it's taken | Typical onset | Watch for |
|---|---|---|---|---|
| Vibegron (Gemtesa) | Beta-3 agonist | 75 mg once daily, food optional; may be crushed | Some benefit in 1–2 weeks; judge at 4–8 weeks | Angioedema (labeled; can follow the first dose); urinary retention; raises digoxin; brand cost |
| Mirabegron (Myrbetriq) | Beta-3 agonist | 25–50 mg once daily, swallow whole | Some benefit in 1–2 weeks; judge at 4–8 weeks | Angioedema (labeled); raises blood pressure — not recommended at 180/110 mmHg or above; 25 mg cap if eGFR 15–29 or Child-Pugh B; CYP2D6 interactions; digoxin |
| Trospium chloride | Anticholinergic | 20 mg twice daily, empty stomach 1 hour before meals | Some benefit in 1–2 weeks; judge at 4–8 weeks | Angioedema/anaphylaxis (labeled); dry mouth, constipation; 20 mg once daily at bedtime under 30 mL/min; food blocks absorption |
| Solifenacin (Vesicare) | Anticholinergic | 5 mg once daily, may go to 10 mg | Some benefit in 1–2 weeks; judge at 4–8 weeks | Angioedema/anaphylaxis (labeled); dry mouth, constipation; not recommended if high QT risk (QTc effect seen at 3x max dose); 5 mg cap with strong CYP3A4 inhibitors |
| Tolterodine ER (Detrol LA) | Anticholinergic | 4 mg once daily, swallow whole | Some benefit in 1–2 weeks; judge at 4–8 weeks | Angioedema/anaphylaxis (labeled); dry mouth, constipation; QT caution with Class IA/III antiarrhythmics; reduce to 2 mg with CYP3A4 inhibitor or organ impairment |
| Darifenacin (Enablex) | Anticholinergic | 7.5 mg once daily, may go to 15 mg after 2 weeks | Some benefit in 1–2 weeks; judge at 4–8 weeks | Angioedema (labeled); constipation prominent; 7.5 mg cap with potent CYP3A4 inhibitors or Child-Pugh B |
| Oxybutynin ER (Ditropan XL) | Anticholinergic | 5–30 mg once daily, swallow whole (shell passes in stool) | Some benefit in 1–2 weeks; judge at 4–8 weeks | Highest CNS penetration of the class — confusion and falls risk in older adults; angioedema (labeled) |
| Oxybutynin IR (Ditropan) | Anticholinergic | Typically 5 mg two to three times daily | Acts faster per dose than the once-daily options; symptom control still builds over 4–8 weeks | Most dry mouth, blurred vision and drowsiness; poor default over 65; reduced sweating in heat; angioedema (labeled) |
What to expect
Set expectations honestly: none of these drugs abolishes urgency. In the pivotal trials the average benefit over placebo is modest — well under one fewer urgency or leakage episode per day, on top of a placebo response that is itself substantial. Total improvement from where you started is larger, which is why a bladder diary matters more than the trial number. Give any of them a fair trial: urgency often eases within one to two weeks, but full effect is judged at four to eight weeks, and dose adjustment is normal — mirabegron's own label sets 4 to 8 weeks as the interval before stepping 25 mg up to 50 mg. Most people stop within the first year, and the reasons cluster into three: side effects (dry mouth and constipation), cost, and the drug simply not working well enough. All three are worth reporting to your prescriber rather than quietly stopping. Keep a two- or three-day bladder diary before and during treatment so the comparison is data, not memory. None of the seven molecules on this page carries an FDA boxed warning, but that is not the same as no serious risk: their labeled warnings include angioedema and anaphylactic reactions on both classes, urinary retention on all of them, and raised blood pressure on mirabegron. If two adequate drug trials plus behavioral therapy fail, the next tier is procedural — bladder onabotulinumtoxinA injection (which does carry a boxed warning for distant spread of toxin effect), sacral neuromodulation, or percutaneous tibial nerve stimulation. That is a urology conversation.
When to get medical help
- Swelling of the face, lips, tongue or throat, or any new trouble breathing or swallowing — this is angioedema, and every drug on this page carries it as a labeled warning: both beta-3 agonists (mirabegron, vibegron) and every antimuscarinic (oxybutynin, tolterodine, solifenacin, darifenacin, trospium). It can occur hours after the very first dose or after later doses, and upper-airway swelling can be life-threatening. Stop the drug and call 911.
- You cannot urinate at all, or your bladder feels painfully full and will not empty — urinary retention is an emergency, and every drug on this page (both the anticholinergics and the beta-3 agonists) can cause it.
- Sudden eye pain, redness, halos around lights, or rapidly blurred vision — possible acute angle-closure glaucoma; the anticholinergics are contraindicated in uncontrolled narrow-angle glaucoma. Stop and seek care the same day.
- New confusion, memory trouble, hallucinations, unusual drowsiness, or a fall in an older adult after starting any anticholinergic (oxybutynin, tolterodine, solifenacin, darifenacin, and to a lesser degree trospium) — this is the anticholinergic-burden effect, not normal aging. It often improves after the drug is stopped or switched, but do not stop on your own: call the prescriber, because the switch is usually to a beta-3 agonist rather than to nothing.
- Home blood pressure readings climbing after starting mirabegron — the drug raises blood pressure, and this is the reason to check it rather than assume.
- Overheating, flushing, or an inability to sweat in hot weather on any anticholinergic — reduced sweating raises the risk of heat exhaustion and heat stroke.
- No bowel movement for several days with abdominal pain, bloating or vomiting while on an anticholinergic — constipation can progress to obstruction.
- Blood in the urine, fever with flank pain, burning with urination, or unexplained weight loss — these are not overactive bladder and need evaluation before any bladder drug is started or continued.
Frequently asked questions
Which overactive bladder medication is safest for an older adult?
As a class, the beta-3 agonists — vibegron and mirabegron — because they add no anticholinergic burden, which is the specific risk that matters most after 65 (confusion, sedation, falls). Among the anticholinergics, trospium crosses into the brain least. Oxybutynin, especially immediate-release, is the one geriatric prescribing guidance most consistently advises against in older adults with cognitive impairment. Two caveats worth carrying into the visit: mirabegron is still capped at 25 mg daily if your eGFR is 15–29, and both classes carry the angioedema warning. Cost often pushes in the opposite direction, and that trade-off is worth naming out loud with your prescriber.
Do any overactive bladder drugs have an FDA boxed warning?
None of the seven molecules compared here — mirabegron, vibegron, solifenacin, tolterodine, oxybutynin (immediate- and extended-release), trospium, darifenacin — carries an FDA boxed warning. That is not the same as no serious risk. Their labeled Warnings and Precautions include angioedema and anaphylactic reactions on both classes, urinary retention on all of them, blood pressure elevation on mirabegron, and QT language on solifenacin and tolterodine. Bladder onabotulinumtoxinA, a later-line injected option, does carry a boxed warning for distant spread of toxin effect.
Is mirabegron or vibegron better?
They share a mechanism and their trial benefits are broadly comparable. The practical separators are on the label, not in the efficacy data: mirabegron is not recommended in severe uncontrolled hypertension (180/110 mmHg or above), inhibits CYP2D6 — which matters if you take metoprolol, flecainide or a tricyclic — and is capped at 25 mg daily in severe renal or moderate hepatic impairment. Vibegron carries no blood-pressure restriction — though it is not recommended below an eGFR of 15, on dialysis, or in Child-Pugh C either — can be crushed, and is the one separately approved for men already on drug therapy for an enlarged prostate. Both raise digoxin levels and both carry the angioedema warning. Formulary coverage frequently decides it.
How long before an overactive bladder medication works?
Urgency often begins easing within one to two weeks, but the fair point to judge whether a drug is working is four to eight weeks at an adequate dose — that is the interval mirabegron's label uses before stepping 25 mg up to 50 mg. Immediate-release oxybutynin acts faster after each dose, which feels quicker but does not mean better overall control. If nothing has changed by eight weeks, that is a reason to switch drug or class rather than to keep escalating.
Can I take an anticholinergic and a beta-3 agonist together?
Combination therapy is used in practice when one drug alone is not enough, but it raises the risk of urinary retention meaningfully — both the mirabegron and vibegron labels flag that risk specifically for people taking a muscarinic antagonist for overactive bladder at the same time. It is a decision for a prescriber who knows whether you have any bladder outlet obstruction, not something to assemble yourself from leftover prescriptions.
Will drinking less water fix overactive bladder?
Reducing total fluid helps modestly, but severe restriction backfires: concentrated urine irritates the bladder and worsens urgency, and it risks dehydration and constipation, which itself aggravates bladder symptoms. The higher-yield changes are which fluids and when — cutting caffeine and alcohol, and front-loading fluid earlier in the day if nighttime trips are the main problem.
What happens if medication and bladder training both fail?
That is the point at which urology guidelines move to procedural options rather than a third or fourth pill: onabotulinumtoxinA injected into the bladder wall, sacral neuromodulation, or percutaneous tibial nerve stimulation. Before that step, it is worth confirming the diagnosis — blood in the urine, recurrent infection, incomplete emptying, or a neurological cause can all masquerade as ordinary overactive bladder.
Sources
Treatment-role framing follows standard US clinical guidelines; each drug links to its FDA label and our rating. This is general reference information, not medical advice, and not a recommendation to take any drug — the choice is a decision to make with a clinician. If you are in crisis, call or text 988 (the US Suicide & Crisis Lifeline).